OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I
OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I
复制标题
DOI：
10.1097/iae.0000000000001125
复制
发表时间：
2017-01-01
影响因子：
3.3
通讯作者：
Park, Won Soon
中科院分区：
文献类型：
--
作者：
Yoon, Je Moon;Shin, Dong Hoon;Park, Won Soon
目的：探讨I区1型早产儿视网膜病变的解剖和屈光结果。方法：对51例I区1型早产儿视网膜病变101只眼的病历进行分析。婴儿接受常规激光光凝治疗（I组），联合玻璃体内贝伐单抗注射和I区保留激光治疗（II组），或玻璃体内贝伐单抗与延迟激光治疗（III组）。比较三组患者视网膜褶皱、椎间盘拖拽、视网膜后组织遮挡后极视野、视网膜脱离、早期屈光不正等不良解剖结果的比例。结果：51例婴儿出生时平均胎龄24.3 +/- 1.1周，出生体重646 +/- 143 g。在第一组中，44只眼中有10只（22.7%）的解剖结果不佳。相比之下，在II组和III组中，所有的眼睛都显示出良好的解剖结果，没有重新激活或再治疗。III组屈光不正近视程度低于I组和II组（I组为24.62 +/- 4.00 D， II组为25.53 +/- 2.21 D， III组为21.40 +/- 2.19 D, P < 0.001）。结论：在I区早产儿1型视网膜病变中，玻璃体内贝伐单抗联合或延迟激光治疗比单独使用常规激光治疗具有更好的解剖学结果。此外，玻璃体内贝伐单抗延迟激光治疗可减少近视屈光不正。
Purpose: To investigate the anatomical and refractive outcomes in patients with Type 1 retinopathy of prematurity in Zone I.Methods: The medical records of 101 eyes of 51 consecutive infants with Type 1 retinopathy of prematurity in Zone I were analyzed. Infants were treated by conventional laser photocoagulation (Group I), combined intravitreal bevacizumab injection and Zone I sparing laser (Group II), or intravitreal bevacizumab with deferred laser treatment (Group III). The proportion of unfavorable anatomical outcomes including retinal fold, disc dragging, retrolental tissue obscuring the view of the posterior pole, retinal detachment, and early refractive errors were compared among the three groups.Results: The mean gestational age at birth and the birth weight of all 51 infants were 24.3 +/- 1.1 weeks and 646 +/- 143 g, respectively. In Group I, an unfavorable anatomical outcome was observed in 10 of 44 eyes (22.7%). In contrast, in Groups II and III, all eyes showed favorable anatomical outcomes without reactivation or retreatment. The refractive error was less myopic in Group III than in Groups I and II (spherical equivalent of 24.62 +/- 4.00 D in Group I, 25.53 +/- 2.21 D in Group II, and 21.40 +/- 2.19 D in Group III; P < 0.001).Conclusion: In Type 1 retinopathy of prematurity in Zone I, intravitreal bevacizumab with concomitant or deferred laser therapy yielded a better anatomical outcome than conventional laser therapy alone. Moreover, intravitreal bevacizumab with deferred laser treatment resulted in less myopic refractive error.